Founded in 2019, Linus Biotechnology (LinusBio) is a precision exposome medicine company born out of research from Mount Sinai’s Exposomic Research Labs. The company’s proprietary platform analyzes a single strand of hair to track an individual’s molecular exposures over time, offering groundbreaking insights into diseases previously lacking objective diagnostics.
By late 2022, Linus Biotechnology (LinusBio) had strong scientific momentum but no scalable operations to bring its exposome-based diagnostics to market.
The inflection point arrived in December 2022, when Ronak Kadakia joined as Chief Operating Officer. Her mission: turn LinusBio’s R&D potential into commercial performance.
Within just 18 months, the company scaled to 300% year-over-year revenue growth and raised over $30 million, transforming into a commercial-stage precision medicine leader.
Appointing a COO to Turn Breakthrough Science into Market Growth
When Kadakia stepped in, LinusBio’s challenge was clear — operational inefficiency was slowing down market readiness.
With a background in finance, strategy, and commercialization, Kadakia brought structure and discipline to a fast-evolving scientific business.
She focused on three priorities that would set LinusBio’s transformation in motion:
- Establish operational and regulatory infrastructure to enable product launch.
- Align scientific and business teams under a unified commercial strategy.
- Secure capital to fund rapid scaling and global expansion.
Her leadership catalyzed a company reorganization that turned breakthrough science into a growing business capable of reaching millions.
Building Speed and Scale to Commercialize Innovation
Kadakia’s playbook centered on acceleration — taking LinusBio from research-ready to commercially operational in record time.
She led the buildout of a CLIA-certified laboratory, expanded the team with key executives, and introduced automation to scale testing throughput.
These actions established LinusBio’s ability to deliver its first commercial product, ClearStrand ASD, to nearly every U.S. state while advancing new pipeline programs in ALS, ADHD, inflammatory bowel disease, and cancer diagnostics.
From Startup Roots to Global Impact: LinusBio from 2022 to 2025
Below highlights LinusBio’s transformation from R&D-focused startup to commercial-stage precision medicine company.
- December 2022: Ronak Kadakia joined as COO to lead operational transformation and commercialization efforts.
- March 2023: Company relocated to the NJ Bioscience Center in North Brunswick, NJ, establishing new lab and operations center.
- May 2023: Laboratory work began within two months of lease signing, accelerating speed to operationalization.
- Late 2023: Achieved full CLIA certification, allowing launch of hair-based test as a Laboratory Developed Test (LDT).
- 2023–2024: Raised over $30 million across Series A, A2, and A3 rounds; valuation doubled to an estimated $170 million by 2024.
- 2024–2025: Launched ClearStrand ASD nationally across 49 U.S. states with 80–90% diagnostic accuracy.
- 2025: Expanded internationally through partnerships in Japan and achieved publication in The Lancet eBioMedicine identifying ALS biomarker.
These milestones chart LinusBio’s evolution from concept to commercialization, culminating in industry recognition and measurable growth.
Investing in Automation and Partnerships to Sustain Momentum
To sustain momentum, Kadakia introduced automation and global partnerships that multiplied efficiency and expanded reach.
Through collaboration with Y.A.C. Holdings (Japan), LinusBio integrated robotics with its proprietary laser-based hair analysis, significantly boosting testing capacity.
A new alliance with Coralis Health embedded LinusBio’s autism screening test into nationwide care pathways, reducing diagnosis times from years to weeks.
Partnerships with Novozymes and academic institutions further validated and diversified LinusBio’s platform across biological and environmental research — strengthening credibility and scientific value.
Delivering Record Results and Industry Recognition
By mid-2024, the results were clear: LinusBio had executed one of the fastest operational ramp-ups in precision medicine history.
- 300%+ year-over-year revenue growth sustained from commercialization through 2024.
- Over $30 million raised in under two years amid a competitive funding environment.
- CLIA certification, nationwide rollout, and initial international expansion achieved in 18 months.
- Recognized as “Overall MedTech Company of the Year 2024” by BioTech Breakthrough Awards.
Under Kadakia’s leadership, LinusBio turned innovation into measurable business performance.
Building the Future of Precision Exposome Medicine
Today, LinusBio stands at the intersection of operational excellence and scientific discovery.
By pairing exposome sequencing with scalable infrastructure, the company redefined early disease detection and reshaped the diagnostics landscape.
The decisive hire of a strategic COO from Christian & Timbers not only fueled financial growth but also built the foundation for long-term leadership in precision medicine — proving that disciplined operations can amplify innovation and drive industry-defining impact.